In the present study, we demonstrated that BBR intervention concurrently increased BAT mass and activity, thereby contributing to a reduction in BW and improvement in insulin sensitivity in patients with NAFLD. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.